al from Canada
01-17-2006, 10:35 PM
We are all aware of the clinical trials with lapatinib but there are a few other small molecule HER inhibitors that are also undergoing clinical trials. The important thing about small molecule drugs is that they cross the blood / brain barrier.
Al
Tarceva (erlotinib)
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane, North Central Cancer Treatment Group
Erlotinib and Bevacizumab (avastin) in Treating Women With Stage IV Breast Cancer. Memorial Sloan-Kettering Cancer Center
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/neu Overexpression. Jonsson Comprehensive Cancer Center
Iressa (gefitinib)
Breast : Gefitinib has very little activity as a single agent in the overall breast cancer population, but preclinical data have suggested synergy with tamoxifen and other hormonal agents, as well as other growth factor inhibitors.
A Pilot Trial Incorporating ZD1839 (IRESSA) into Adjuvant Therapy for Breast Cancer - BRE02-43. Hoosier Oncology Group
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer. EORTC
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer. No rris Cotton Cancer Center
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer. Eastern Cooperative Oncology Group (ECOG)
Al
Tarceva (erlotinib)
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane, North Central Cancer Treatment Group
Erlotinib and Bevacizumab (avastin) in Treating Women With Stage IV Breast Cancer. Memorial Sloan-Kettering Cancer Center
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/neu Overexpression. Jonsson Comprehensive Cancer Center
Iressa (gefitinib)
Breast : Gefitinib has very little activity as a single agent in the overall breast cancer population, but preclinical data have suggested synergy with tamoxifen and other hormonal agents, as well as other growth factor inhibitors.
A Pilot Trial Incorporating ZD1839 (IRESSA) into Adjuvant Therapy for Breast Cancer - BRE02-43. Hoosier Oncology Group
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer. EORTC
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer. No rris Cotton Cancer Center
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer. Eastern Cooperative Oncology Group (ECOG)